Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Attention-Deficit/Hyperactivity Disorder (ADHD)
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Trial Timeline
Oct 1, 2008 → Dec 1, 2008
NCT ID
NCT00776009About Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo is a approved stage product being developed by Novartis for Attention-Deficit/Hyperactivity Disorder (ADHD). The current trial status is completed. This product is registered under clinical trial identifier NCT00776009. Target conditions include Attention-Deficit/Hyperactivity Disorder (ADHD).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00776009 | Approved | Completed |
Competing Products
18 competing products in Attention-Deficit/Hyperactivity Disorder (ADHD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| ABT-089 + atomoxetine + placebo | AbbVie | Phase 2 | 52 |
| ABT-089 + Placebo | AbbVie | Phase 2 | 52 |
| ABT-089 | AbbVie | Phase 2 | 52 |
| ABT-089 + placebo | AbbVie | Phase 2 | 52 |
| MK0249 + Concerta (methylphenidate) + Placebo | Merck | Phase 2 | 52 |
| SPN-812 | Supernus Pharmaceuticals | Approved | 80 |
| IR Viloxazine + Placebo | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SPN-812 | Supernus Pharmaceuticals | Approved | 80 |
| 100mg SPN-812 + Placebo | Supernus Pharmaceuticals | Approved | 80 |
| SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| Placebo + SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812 | Supernus Pharmaceuticals | Phase 2 | 47 |
| SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| TD-9855 + TD-9855 + Placebo | Theravance Biopharma | Phase 2 | 47 |